PANews October 21 news, according to an official OpenAI announcement, OpenAI has acquired Orchestra Bio, a drug R&D collaboration platform. The platform helps biopharmaceutical teams coordinate complex drug development processes, allowing scientists and project leads to delegate the monitoring and tracking of research and trials to AI agents. OpenAI stated that it will integrate Orchestra's team and technology with Rosalind, its life sciences research AI model and tool, to help new therapies reach patients faster.
OpenAI acquires drug R&D collaboration platform Orchestra Bio
Noticias relacionadas
Financiación semanal | Kalshi completa una ronda de financiación Serie G de 1.000 millones de dólares, liderada por Sequoia Capital y Wellington Management.
Kalshi completó una ronda de financiación Serie G de $1 mil millones, alcanzando una valoración post-money de $40 mil millones, casi el doble de su valoración d...